Data2Life Ltd.

data2life.com

High-Tech Company

Suspended Operations Q4/2020

TECH VERTICALS

Digital Health, Healthcare IT, Healthtech, Life Sciences, Medical Cannabis, MedTech

General Data

Sector	Digital Health
Company Stage:	Initial Revenues
Established	2015
Number of Employees	10
Reg. Number:	abCDe

DESCRIPTION

Data2Life serves the life sciences and healthcare industries with real-world intelligence and easy-to-use analytical tools on drug events and trends. By combining, normalizing and cross-validating data from regulatory agencies, clinical electronic health records and social media, Data2Life provides broader and clearer visibility into drug effects experienced by patients after launch.

Data2Life was born to redefine drug Intelligence, by extracting the patient-voice and creating value-based insights to enable the journey to a personalized healthcare and treatment development.

Data2Life started-off by providing ‘evidence-based’ signal comparison of drug adverse-events, using big-data and multiple real-world-data sources. Using AI-algorithms to analyze the massive amount of healthcare data, Data2Life technology was able to put into perspective and effectively prioritize an overwhelming amount of potential signals. This has significantly shortened the average signal processing time, as well as increased the PV-analyst confidence in signal validation.

The growing mainstream consumption of Cannabis has opened the door for medical licensing and potential regulation. Stress relief, pain management, as well as treatment for anything from acne to cancer - a wide variety of use cases are available to the CannaPharma industry. However, this can only happen if existing data can be harnessed.

TECHNOLOGY

Data2Life healthcare proficiency and cutting-edge technology is able to crawl real world data and transform it into actionable insights . These are used to address critical use-cases, such as: drug intelligence, adverse events (AE) signal detection, and more. In other words, Data2Life offering helps pharmas and various healthcare stakeholders to gain deeper and faster visibility into how drugs perform and affect people’s life – during clinical and post-marketing stages.
Our products’ goal is to go beyond shortening drug development cycles, we aim to: save lives, protect our customers’ reputation, and enrich the drug-development cycle by bringing patients’ voices in and increasing data-driven decision-making.
Data2Life products also aim to save IT costs, and enable our customers to focus on creating core-value for their businesses and avoid a waste of time, money and resources on managing IT applications. This is why we develop cloud-native SaaS products, that can be deployed natively over HIPAA-compliant public cloud, as well as on-premise (for customers requesting so).

	TARGET MARKETS
	HMO, Medical Professionals, Hospitals , BioPharmas R&D, Marketing teams, Drug Safety Departments, Health Authorities, Regulatory Affairs and Safety Research Teams

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	14 Beit Hillel St.
City	Tel Aviv
Country	Israel
Zip	6701714

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Itzik Lichtenfeld	CEO & Co-Founder
Ms. Limor Epstein	Chief Medical Informatics Officer & Co-Founder
Ms. Natalie Gavrielov	CSO

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	CEO, Mor R&A
abC Defghij	Board Member	CEO & Co-Founder, Data2Life Ltd.
abC Defghij	Board Member	Chairman & Co-owner, MIKAL GROUP
abC Defghij	Board Member	N\A

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Jun. 01, 2017

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Family Office	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

Seed

Jun. 01, 2015

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Sep. 01, 2015

R&D

Contributor	Type	Amount	Remarks
abC Defghij	Corporate Accelerator	abCDe

Non-Equity Assistance

Jan. 01, 2015

Seed

Contributor	Type	Amount	Remarks
abC Defghij	Technology Transfer Company	abCDe

Last Updated:	abCDe
IVC Number:	abCDe